Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD019 plus Trastuzumab and mFOLFOX-6 in HER2+ Esophageal and Gastric Cancer
NCT02205463Phase 1Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Dec 2014
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of tesevatinib in esophageal adenocarcinoma (EAC), adenocarcinoma of the gastroesophageal junction and Adenocarcinoma of the stomach (GC), sponsored by NYU Langone Health. Planned start Dec 2014; status: withdrawn.
02
Drugs
tesevatinib
03
Conditions
esophageal adenocarcinoma (EAC)adenocarcinoma of the gastroesophageal junctionAdenocarcinoma of the stomach (GC)
Beyond the preview
Go deeper on NCT02205463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205463.